• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

    2/13/24 5:17:31 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRTX alert in real time by email
    SC 13G/A 1 tv02209-vertexpharmaceutical.htm SCHEDULE 13G/A vertexpharmaceuticalsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 10)*

    Name of issuer:  Vertex Pharmaceuticals Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  92532F100

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  92532F100

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    342,185

    7.  SOLE DISPOSITIVE POWER

    21,173,929

    8.  SHARED DISPOSITIVE POWER

    1,107,800

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    22,281,729

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    8.65%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Vertex Pharmaceuticals Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    50 Northern Avenue
    Boston, MA 02210

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    92532F100

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $VRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VRTX

    DatePrice TargetRatingAnalyst
    5/7/2025Outperform → Peer Perform
    Wolfe Research
    5/6/2025$503.00Outperform → Market Perform
    Leerink Partners
    4/22/2025$535.00Overweight
    Cantor Fitzgerald
    2/12/2025$408.00 → $424.00Sell → Hold
    Canaccord Genuity
    2/11/2025Sell → Hold
    Canaccord Genuity
    1/30/2025$460.00Overweight → Equal Weight
    Wells Fargo
    12/20/2024$600.00 → $535.00Buy
    H.C. Wainwright
    12/19/2024Outperform → Perform
    Oppenheimer
    More analyst ratings

    $VRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Upadhyay Suketu returned 1,001 shares to the company and was granted 796 shares, decreasing direct ownership by 8% to 2,354 units (SEC Form 4)

      4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

      5/5/25 5:00:58 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Thornberry Nancy was granted 398 shares, increasing direct ownership by 24% to 2,035 units (SEC Form 4)

      4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

      5/5/25 4:59:17 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schneider Jennifer was granted 796 shares, increasing direct ownership by 86% to 1,718 units (SEC Form 4)

      4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

      5/5/25 4:57:54 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Vertex Appoints Nancy Thornberry to its Board of Directors

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director. Ms. Thornberry has more than 35 years of experience in the pharmaceutical and biotech industries, spanning drug discovery, development and commercialization. She founded and served as Chief Executive Officer of Kallyope until 2021 and remains on its Board of Directors and is Chair of Research & Development. Prior to joining Kallyope, Ms. Thornberry spent more than 30 years at Merck & Co., Inc., most recently as Senior Vice President and Global Franchise Head, Diabetes and Endocrinology, with responsibility for discovery and clinical

      12/5/23 4:01:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Appoints Michel Lagarde to its Board of Directors

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Michel Lagarde has been appointed to its Board of Directors as an independent director. Mr. Lagarde is a senior health care and business leader with global expertise, currently serving as Chief Operating Officer and Executive Vice President of Thermo Fisher Scientific Inc. Prior to Thermo Fisher, Mr. Lagarde served as President and Chief Operating Officer of Patheon, a contract manufacturer to the biopharma industry, and as a Managing Director at JLL Partners, a private equity firm investing in health care services. "We are delighted to have Michel join the Vertex Board. His deep experience across numerous segments of

      10/5/23 8:00:00 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that E. Morrey Atkinson, Ph.D., has been appointed Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations, effective immediately. Dr. Atkinson has served as Senior Vice President of Global Commercial Manufacturing and Supply Chain since July 2020. This new role and function unifies responsibility for small molecule, cell and gene therapies across preclinical, clinical and commercial biopharmaceutical sciences, manufacturing operations and global supply chain. "Over the last three years, Morrey has played a vital role in building out our commercial manufa

      8/29/23 9:00:00 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vertex Pharma downgraded by Wolfe Research

      Wolfe Research downgraded Vertex Pharma from Outperform to Peer Perform

      5/7/25 8:37:12 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Pharma downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Vertex Pharma from Outperform to Market Perform and set a new price target of $503.00

      5/6/25 8:04:29 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on Vertex Pharma with a new price target

      Cantor Fitzgerald resumed coverage of Vertex Pharma with a rating of Overweight and set a new price target of $535.00

      4/22/25 7:35:34 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

      SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

      4/10/24 12:14:10 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

      SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

      2/13/24 5:17:31 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

      SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

      2/9/24 6:19:03 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Vertex Pharmaceuticals Incorporated

      10-Q - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)

      5/6/25 4:04:39 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Pharmaceuticals Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)

      5/5/25 4:10:03 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Vertex Pharmaceuticals Incorporated

      DEFA14A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)

      4/3/25 4:04:58 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vertex Reports First Quarter 2025 Financial Results

      — Total revenue of $2.77 billion, a 3% increase compared to Q1 2024; raised the low end of total revenue guidance by $100 million to a new range of $11.85 to $12 billion — — Strong progress with CASGEVY®, ALYFTREK™ and JOURNAVX™ launches — — Povetacicept (pove) IgAN Phase 3 interim analysis (IA) cohort fully enrolled and zimislecel Phase 3 program to complete dosing this quarter, setting up potential filings in 2026; inaxaplin Phase 3 IA cohort on track to complete enrollment in the second half of 2025 — — Four programs already in pivotal development, with pivotal study of pove in primary membranous nephropathy (pMN) to start this year — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

      5/5/25 4:01:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner International Award "for pioneering research into the cellular and molecular mechanisms underlying the genetic disease cystic fibrosis, leading to the development of transformative drug therapies based on these mechanisms, thereby improving and saving countless lives." Negulescu shares the award with Michael J. Welsh, M.D., University of Iowa. "For more than 20 years, Paul and the team of dedicated Vertex researchers have focused on discovering and developing breakthrough therapies for people living with cystic fibrosis (CF). P

      4/11/25 5:30:00 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex to Announce First Quarter 2025 Financial Results on May 5th

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals First Quarter 2025 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast

      4/7/25 4:05:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    Financials

    Live finance-specific insights

    See more
    • Vertex Reports First Quarter 2025 Financial Results

      — Total revenue of $2.77 billion, a 3% increase compared to Q1 2024; raised the low end of total revenue guidance by $100 million to a new range of $11.85 to $12 billion — — Strong progress with CASGEVY®, ALYFTREK™ and JOURNAVX™ launches — — Povetacicept (pove) IgAN Phase 3 interim analysis (IA) cohort fully enrolled and zimislecel Phase 3 program to complete dosing this quarter, setting up potential filings in 2026; inaxaplin Phase 3 IA cohort on track to complete enrollment in the second half of 2025 — — Four programs already in pivotal development, with pivotal study of pove in primary membranous nephropathy (pMN) to start this year — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

      5/5/25 4:01:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex to Announce First Quarter 2025 Financial Results on May 5th

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals First Quarter 2025 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast

      4/7/25 4:05:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Reports Fourth Quarter and Full Year 2024 Financial Results

      — Full year product revenue of $11.02 billion, a 12% increase compared to full year 2023 — — Company provides full year 2025 total revenue guidance of $11.75 to $12.0 billion — — ALYFTREK™ approved in the U.S. for patients ages 6+ with cystic fibrosis; JOURNAVX™ approved in the U.S. for moderate-to-severe acute pain — — Diverse late-stage clinical pipeline accelerates with four programs in pivotal development — — Stuart Arbuckle, Chief Operating Officer, announces intent to retire July 1, 2025; as part of planned transition, Charlie Wagner, Chief Financial Officer, to assume additional role of Chief Operating Officer; Duncan McKechnie, SVP and current head of North America Commercia

      2/10/25 4:01:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • January 30, 2025 - FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

      For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain.  Journavx is the first dr

      1/30/25 5:46:14 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

      For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

      12/8/23 11:12:21 AM ET
      $BLUE
      $VRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • FDA Approval for TRIKAFTA (COPACKAGED) issued to VERTEX PHARMS INC

      Submission status for VERTEX PHARMS INC's drug TRIKAFTA (COPACKAGED) (SUPPL-11) with active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 212273, Application Classification: Labeling

      8/4/23 4:36:00 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care